Home

Richard J Markham

CIK 1362743 · last filed 2019-06-14

Richard J Markham is a corporate insider who has filed 21 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing, for VXRT, was dated Jun 14, 2019. Across all open-market trades the lifetime net is +$8.7M, making them a net buyer over the disclosed history. 3 SEC filings were submitted jointly with Care Capital III LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

21

Lifetime Open-Market Net

$8.71M

Filer Profile

Reported Address
C/O CARE CAPITAL LLC
47 HULFISH STREET, SUITE 310
PRINCETON, NJ 08542
Related Filers
Care Capital III LLC — 3 joint filings, latest 2015-05-12
Care Capital Investments III L.P. — 3 joint filings, latest 2015-05-12
Care Capital Offshore Investments III LP — 3 joint filings, latest 2015-05-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Vaxart, Inc. (VXRT) Delisted Director 30,793,670 $0.32 $9.85M $0 2 2019-06-14
NephroGenex, Inc. (NRX) Delisted Director 4,241,097 — — $9.48M 2 2015-05-04
ACURA PHARMACEUTICALS, INC (ACUR) Delisted Director 0 — — -$766.0K 13 2013-01-03
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Director 1,558,104 $10.19 $15.88M $0 3 2011-05-26

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-06-14 Vaxart, Inc. (VXRT) Delisted Grant (A) — $0 EDGAR
2018-02-15 Vaxart, Inc. (VXRT) Delisted Grant (A) +30,793,670 $0 EDGAR
2015-05-04 NephroGenex, Inc. (NRX) Delisted Grant (A) — $0 EDGAR
2014-02-19 NephroGenex, Inc. (NRX) Delisted Mixed +4,241,097 $9.48M EDGAR
2013-01-03 ACURA PHARMACEUTICALS, INC (ACUR) Delisted Grant (A) — $0 EDGAR
2012-01-04 ACURA PHARMACEUTICALS, INC (ACUR) Delisted Grant (A) — $0 EDGAR
2011-05-26 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) — $0 EDGAR
2011-04-04 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) — $0 EDGAR
2011-01-03 ACURA PHARMACEUTICALS, INC (ACUR) Delisted Grant (A) — $0 EDGAR
2010-12-01 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Conv (C) +1,558,104 $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.